Amylyx Pharmaceuticals Analyst Price Targets

Amylyx Pharmaceuticals Inc

AMLXNASDAQ

Trade with Public

$27.33

0.993.76%

Dern. MÀJ: Oct 20, 4:10 AM

$27.31

0.973.68%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Amylyx Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amylyx Pharmaceuticals (AMLX).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

10Buy

1Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$29Upside to Avg. PT+5.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$32→$39
Aug 27, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$55→$57
Aug 19, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$30→$42
Aug 19, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$40→$55
Aug 19, 2026	Baird	Joel Beatty	PT Raise	Outperform	$28→$52
Aug 18, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$34→$55
Aug 17, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$24→$30
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$20→$26
Jul 20, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$21→$24
Jun 25, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$30→$40
Apr 28, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$19→$21
Mar 25, 2026	HC Wainwright & Co.	Andrew S. Fein	Maintained	Buy	$34
Mar 19, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$25→$30
Mar 4, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$28→$34
Mar 3, 2026	Stifel	James Condulis	Initiate	Buy	$21
Feb 20, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$15→$19
Feb 10, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$20→$28
Nov 7, 2025	HC Wainwright & Co.	Andrew Fein	PT Raise	Buy	$16→$20
Oct 17, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$12→$20
Oct 16, 2025	Baird	Joel Beatty	PT Raise	Outperform	$10→$19

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.

Benzinga Newsdesk

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Amylyx Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

People Also Watch

People Also Watch

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

PROGuggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PROMizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PROGuggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PROBaird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PROHC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Amylyx Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

PROGuggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PROMizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PROGuggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PROBaird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PROHC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55